Nucleophosmin in leukemia: Consequences of anchor loss
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
31009764
DOI
10.1016/j.biocel.2019.04.007
PII: S1357-2725(19)30080-9
Knihovny.cz E-zdroje
- Klíčová slova
- Immunotherapy, Interaction, Leukemia, Mutation, Nucleophosmin,
- MeSH
- akutní myeloidní leukemie farmakoterapie genetika imunologie metabolismus MeSH
- cílená molekulární terapie MeSH
- imunoterapie MeSH
- jaderné proteiny chemie genetika metabolismus MeSH
- lidé MeSH
- multimerizace proteinu MeSH
- mutace MeSH
- nukleofosmin MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- jaderné proteiny MeSH
- NPM1 protein, human MeSH Prohlížeč
- nukleofosmin MeSH
Nucleophosmin (NPM), one of the most abundant nucleolar proteins, has crucial functions in ribosome biogenesis, cell cycle control, and DNA-damage repair. In human cells, NPM occurs mainly in oligomers. It functions as a chaperone, undergoes numerous interactions and forms part of many protein complexes. Although NPM role in carcinogenesis is not fully elucidated, a variety of tumor suppressor as well as oncogenic activities were described. NPM is overexpressed, fused with other proteins, or mutated in various tumor types. In the acute myeloid leukemia (AML), characteristic mutations in NPM1 gene, leading to modification of NPM C-terminus, are the most frequent genetic aberration. Although multiple mutation types of NPM are found in AML, they are all characterized by aberrant cytoplasmic localization of the mutated protein. In this review, current knowledge of the structure and function of NPM is presented in relation to its interaction network, in particular to the interaction with other nucleolar proteins and with proteins active in apoptosis. Possible molecular mechanisms of NPM mutation-driven leukemogenesis and NPM therapeutic targeting are discussed. Finally, recent findings concerning the immunogenicity of the mutated NPM and specific immunological features of AML patients with NPM mutation are summarized.
Citace poskytuje Crossref.org
NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization